Condition: NK T-Cell Lymphoma · CART Therapy · CD7-positive Relapsed/Refractory Lymphoid Hematologic Malignancies · Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
This is a single-arm, open-label, single-center, phase I study. The primary objective is to evaluate the safety of CD7 Chimeric Antigen Receptor-T(CAR-T) therapy for patients with CD7-positive relapsed or refractory natural killer/T cell lymphoma, and to evaluate the pharmacokinetics of CD7 CAR-T in patients。
This description comes directly from the study's public registry record.
Heng Mei, Ph.D&M.D · 027-8572600 · hmei@hust.edu.cn
Yinqiang Zhang · 15007101371 · zhang_yq@hust.edu.cn
Always discuss trial participation with your own doctor first.
| Union Hospital | Wuhan, Hubei, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06732492